Loading...
A Phase 1, Open-Label Study in Healthy Subjects to Evaluate the Absolute Bioavailability of AG-221 by a Microtracer Approach
INTRODUCTION: The purpose of this study was to evaluate the absolute bioavailability (BA) of AG-221 following a single oral dose of 100 mg AG-221 and an intravenous (IV) dose of ~ 100 μg AG-221 containing approximately 300 nCi of [(14)C]-AG-221. METHODS: This was a phase 1, open-label study. Six sub...
Saved in:
| Published in: | Oncol Ther |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Springer Healthcare
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7360017/ https://ncbi.nlm.nih.gov/pubmed/32700065 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40487-019-0097-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|